Pfizer Recalls Some Blood Pressure Drugs, Citing Cancer Risk
The move follows recalls of other medications found to have higher levels of potential carcinogens.
The move follows recalls of other medications found to have higher levels of potential carcinogens.
The move follows recalls of other medications found to have higher levels of potential carcinogens.
The move follows recalls of other medications found to have higher levels of potential carcinogens.
Shots: Glenmark has launched Remogliflozin (SGLT2 inhibitors, 100mg, ) + Vildagliptin (DPP4 inhibitors, 50mg,) + Metformin (500/1000mg) as FDC for the management of T2D in […]
Date: October 19, 2020 Issue #: 1609 Summary: The FDA has approved two additional doses (3 mg and 4.5 mg) of the glucagon-like peptide-1 (GLP-1) […]
Copyright © 2024 | WordPress Theme by MH Themes